Who Needs Monitoring for Tysabri-Related PML?
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Literacy to Specific Occupational Risk
If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is crucial. This condition, caused by the John Cunningham virus, can lead to serious neurological symptoms. Building on decades of medical knowledge about immunosuppression and viral reactivation, this page outlines key risk factors and monitoring strategies to help you navigate ongoing care.
Bridging General Health Knowledge to Tysabri-Associated PML
Building on the foundational understanding of general health principles, we now focus on the specific medical and legal landscape surrounding Tysabri (natalizumab) and its association with progressive multifocal leukoencephalopathy (PML). Tysabri is a biologic therapy approved for relapsing forms of multiple sclerosis (MS) and Crohn's disease (CD). Its use carries a significantly increased risk of PML, a rare but often fatal brain infection caused by the JC virus (JCV). The following sections synthesize evidence from FDA-approved labeling and clinical data to describe the medical and risk landscape, with particular attention to settlement-related considerations for affected patients.
Clinical Presentation and Diagnosis of PML
PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. It is caused by reactivation of the JC virus, which damages oligodendrocytes and leads to progressive demyelination. Clinical presentation varies but commonly includes subacute onset of neurological deficits such as weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Brain biopsy may be confirmatory but is rarely required. The disease usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri Pharmacology and Reported Adverse Effects
Tysabri is a monoclonal antibody that binds to alpha-4 integrins, preventing lymphocyte migration into the central nervous system and gut. This mechanism reduces inflammation in MS and CD but also impairs immune surveillance against JCV. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 MS patients treated for a median of 120 weeks; both had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and urinary tract infections.
Mechanistic Pathways Linking Tysabri to PML
Tysabri's inhibition of lymphocyte trafficking to the brain reduces the ability to control JCV replication. The drug's effect on immune surveillance is dose- and duration-dependent. Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies (indicating prior JCV exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.
Adequacy of Warnings Regarding Tysabri and PML
The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML, leading to litigation and settlement programs.
Settlement-Related Considerations for Affected Patients
Patients who develop PML after Tysabri therapy may be eligible for compensation through lawsuit settlements. Settlement criteria typically consider the presence of documented PML diagnosis, evidence of Tysabri exposure, and absence of other confounding causes of immunosuppression. The timeline between exposure and documented harm is critical: PML can occur after variable treatment durations, with risk increasing beyond two years. Patients with anti-JCV antibodies and prior immunosuppressant use are at highest risk. Settlement amounts may account for medical expenses, lost income, pain and suffering, and long-term care needs. Legal claims often allege inadequate warning about PML risk despite the boxed warning, arguing that the risk was not sufficiently communicated to patients or that monitoring recommendations were not followed.
Timeline Between Exposure and Documented Harm
In clinical trials, PML occurred after a median of 120 weeks (approximately 2.3 years) of Tysabri treatment in MS patients, and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that PML can occur earlier, especially in patients with additional risk factors. The latency period from Tysabri initiation to PML diagnosis can range from months to several years. Once symptoms appear, diagnosis and intervention are urgent, as withholding Tysabri and initiating plasma exchange to accelerate drug clearance may improve outcomes. However, even with prompt treatment, most patients experience significant neurological impairment.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and how does it increase the risk of PML?
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It works by preventing immune cells from entering the brain and gut, which reduces inflammation but also impairs immune surveillance against the JC virus, increasing the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the settlement criteria for Tysabri-related PML lawsuits?
Settlement criteria typically require documented PML diagnosis, evidence of Tysabri exposure, and absence of other immunosuppressive causes. Risk factors such as anti-JCV antibodies, treatment duration over two years, and prior immunosuppressant use are considered. The timeline between exposure and harm is critical (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
How is PML diagnosed in Tysabri-treated patients?
Diagnosis involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Brain biopsy may be confirmatory. Symptoms include subacute neurological deficits such as weakness, visual disturbances, and cognitive decline (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- FDA warning Tysabri Progressive Multifocal Leukoencephalopathy
- New York Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
- Does Tysabri cause Progressive Multifocal Leukoencephalopathy
- Tysabri exposure linked to Progressive Multifocal Leukoencephalopathy
- How Tysabri triggers Progressive Multifocal Leukoencephalopathy pathop
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.